https://www.selleckchem.com/pr....oducts/Rapamycin.htm
Fixed-combination bimatoprost 0.03%/timolol 0.5% ophthalmic solution (FCBT; Ganfort , Allergan, an AbbVie company) effectively reduces intraocular pressure (IOP) via complementary mechanisms of action of the agents, but long-term ( 12weeks) safety evaluations of FCBT remain limited. FCBT safety is evaluated herein, with particular focus on hyperemia and eyelash growth, at 24weeks in Chinese patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). In this multicenter, open-label, noncomparative, phase4 study conducted
Like
Comment
Share
